Unilife in talks with customers about planned wind-down of syringe business

By Gareth Macdonald

- Last updated on GMT

iStock/Olivier Le Moal
iStock/Olivier Le Moal

Related tags U.s. securities and exchange commission

Unilfe has started discussing the wind-down of its prefilled syringe business with customers after deciding to focus on wearable drug delivery technologies.

The discussions were announced this week in a US Securities and Exchange Commission (SEC) filing​ in which Unilife also confirmed it will cease investment in its “other product platforms.”

A Unilife spokesman confirmed the plan, telling us that: “The other product platforms are the remainder of our portfolio that are not wearable injectors - prefilled syringes, ocular delivery, etc. We will only focus on wearable injectors going forward​.”

Hikma​ and Sanofi​ are among the firms that buy prefilled syringes from Unilife.

In the filing, Unilife said while it will no longer invest in non-wearables, it will retain associated intellectual property “in the event it becomes financially attractive for the company to further develop, customize, license or sell those products in the future​.”


Unilife announced its plan to focus on its wearables business in July​ as part of a wider cost reduction effort started in January.

The firm has wearable drug delivery technology deals with Amgen​, Sanofi​ and MedImmune​, the global biologics research and development arm of AstraZeneca.

In 2015​, AbbVie signed a strategic deal that granted it access to all of Unilife’s delivery technologies.

Unilife is due to hold a conference call on November 2 to update investors on its financial results and outlook.  

Related topics Drug Delivery Delivery technologies

Related news

Show more

Related products

Related suppliers

Follow us


View more